<DOC>
	<DOCNO>NCT00545233</DOCNO>
	<brief_summary>This 2 arm study ass efficacy safety PEGASYS plus COPEGUS , without concomitant pioglitazone , hepatitis C virus titer treatment-naive patient genotype 1 chronic hepatitis C , insulin resistance . Patients randomize receive either ) PEGASYS 180 micrograms/week + Copegus 1000-1600 mg/day ( accord body weight ) 48 week b ) 16 week pioglitazone ( 30 mg daily 8 week , 45 mg daily 8 week ) , follow PEGASYS 180 micrograms/week + Copegus 1000-1600 mg/day + pioglitazone 45 mg daily 48 week . The anticipated time study treatment 1-2 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Plus COPEGUS ( Ribavirin ) With Without Pioglitazone Treatment-Naive Patients With Chronic Hepatitis C Insulin Resistance .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic hepatitis C , genotype 1 ; insulin resistance . form liver disease ; cirrhosis ; previous treatment chronic hepatitis C ; insulin treatment prior 2 week ; type 1 diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>